The CDC approved two vaccines based on the recommendation of the agency’s independent committee of experts.
The CDC approved the vaccine against respiratory syncytial virus (RSV) for adults age 50-59 who face an elevated risk of severe disease. The vaccine was already approved for individuals age 75 years and older as well as people age 60 to 74 at higher risk. RSV hospitalizes between 58,000-80,000 adults each year and
In addition, the CDC also approved the use of GSK’s meningococcal vaccine in healthy individuals 16–23 years old and people age 10 years and older who have a greater risk of severe illness. Meningococcal bacteria can cause meningitis and bloodstream infections, which can be serious and even fatal.
Full Story: Reuters, MedPage Today
